Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

The Munich Regional Court ruled there was imminent infringement for Merck & Co.’s Keytruda SC in Germany related to ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

This degree of success can become a double-edged sword, though. While the drug has thrived since its first approval back in ...

Finally, Merck is an excellent dividend stock. It offers a juicy forward yield of 3.2% and has increased its payouts by 93.8% ...

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. Learn more about MRK stock here.

A German court has ordered Merck & Co (NYSE: MRK) to halt launch preparations for its new subcutaneous version of Keytruda ...

In early December 2025, Merck reported that the EMA’s Committee for Medicinal Products for Human Use recommended expanding WINREVAIR’s EU indication to cover adults with pulmonary arterial ...

The Food and Drug Administration approved Merck's Keytruda in combination with Padcev to treat certain adults with muscle invasive bladder cancer (MIBC). The FDA said Friday it has approved the drug ...